Free platinum species

Free carboplatin and related platinum species represent the active, non-protein-bound fraction of platinum-based chemotherapeutic agents circulating in the plasma and extracellular fluid. Unlike the protein-bound fraction, which is pharmacologically inactive, free platinum species are capable of entering cells and interacting with cellular targets, primarily DNA. These species exert their anti-tumor effects by forming covalent adducts and cross-links with DNA, which inhibits replication and transcription, ultimately leading to apoptosis in rapidly dividing cancer cells (PubChem, 2024). However, their presence in systemic circulation also leads to significant off-target toxicities, such as ototoxicity and nephrotoxicity, as they react with healthy tissues (FDA, 2022). Therapeutic strategies, such as the administration of sodium thiosulfate, aim to neutralize these free species in the extracellular compartment to mitigate side effects without compromising the intracellular efficacy of the chemotherapy (StatPearls, 2023). Monitoring the concentration of these species is critical for dosing, as their clearance is primarily renal and highly dependent on individual patient kidney function.

Other names

Ultrafilterable platinumNon-protein-bound platinumFree carboplatinActive platinum metabolitesUnbound platinum

Free platinum species act as electrophiles that covalently bind to nucleophilic sites on DNA, particularly the N7 position of guanine and adenine. This binding results in the formation of intra-strand and inter-strand cross-links, which distort the DNA helix, stall DNA polymerase, and trigger DNA damage response pathways leading to cell cycle arrest and apoptosis (StatPearls, 2023; PubChem, 2024).